<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Maternal &amp; Fetal Medicine</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/421DA2DE-E7F4-4BA1-9D55-0A2787E08B5A"><gtr:id>421DA2DE-E7F4-4BA1-9D55-0A2787E08B5A</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:otherNames>Nicholas</gtr:otherNames><gtr:surname>Waddington</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1B57DD47-4242-4081-AE60-A124A6D80305"><gtr:id>1B57DD47-4242-4081-AE60-A124A6D80305</gtr:id><gtr:firstName>Phillip</gtr:firstName><gtr:otherNames>Robert</gtr:otherNames><gtr:surname>Bennett</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B2EBE363-8DB1-4CC6-9F87-0FB78502017C"><gtr:id>B2EBE363-8DB1-4CC6-9F87-0FB78502017C</gtr:id><gtr:firstName>Gennadij</gtr:firstName><gtr:surname>Raivich</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A3EF489B-AAD7-4267-AAE8-072E95D71AC8"><gtr:id>A3EF489B-AAD7-4267-AAE8-072E95D71AC8</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:otherNames>David</gtr:otherNames><gtr:surname>Cooper</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1000709"><gtr:id>CABEE06C-F265-4E6A-937B-F99C7DFD3644</gtr:id><gtr:title>Safety and efficacy of perinatal gene therapy for Neuronopathic Gaucher disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1000709</gtr:grantReference><gtr:abstractText>Gaucher disease is a genetic disease which, in its severe form, results in serious brain damage infant death before two years of age. The disease is incurable with currently-available drugs since they can?t enter the nerves in the brain. Gene therapy has already been used to cure several genetic diseases and, very recently, it has become possible to deliver genes to the brain. Based on this recent finding, we are trying to cure a mouse model of the human brain disease using gene therapy. We will be injecting the gene into bloodstream of fetal and neonatal mice to see if this prevents the onset of brain disease. If this works it may provide a pathway towards treating human beings; at the very least we will learn more about why the disease damages the brain in infants.</gtr:abstractText><gtr:technicalSummary>Neuronopathic (Type II) Gaucher disease is fatal neurodegenerative disease of infancy caused by deficiency of the enzyme Glucocerebrosidase. Unlike the less severe forms of the disease (Types I and III) which are partially treatable by enzyme replacement therapy, neuronopathic gaucher disease is untreatable since intravenous injection of enzyme does not allow uptake by neurons of the central nervous system. Moreover, neuronal pathology is already present in utero. 
A glucocerebrosidase-deficient mouse model of the disease accurately reflects its neonatal lethality likely arising from early motor neuron death. Reconstitution of the enzyme defect in microglia is insufficient to prevent early demise. It is suspected but, as yet, unproven that neuronal glucocerebrosidase expression is essential for prevention of neurological damage. Since pathological changes can already be detected before birth it is possible that even neonatal intervention would be inadequate.
My laboratory specialises in the study of fetal or early neonatal gene transfer for monogenetic disorders. Recently we have observed that administration of adeno-associated virus pseudotype 2/9 to deliver GFP cDNA to neonatal and fetal mice results in very extensive transduction of the central and peripheral nervous system. We have also shown that gene transfer to patient cells can correct the metabolic dysregulation. 
In this grant we propose to deliver an AAV2/9 vector by intravenous injection to the mouse model of neuronopathic Gaucher disease in utero (at 15 days gestation, birth at 20 days) and in D0/1 neonates. We aim to test the hypothesis that early reconstitution of neuronal expression of glucocerebrosidase is sufficient to prevent the early demise in these mice. This study would also aim to differentiate the efficacy of fetal and neonatal intervention. 
From Professor Stefan Karlsson (Lund, Sweden) we have acquired a breeding colony of glucocerebrosidase-deficient mice the homozygotes of which display a clear phenotype of early neurological damage and demise.</gtr:technicalSummary><gtr:fund><gtr:end>2014-09-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>489717</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Presentation at the British Society for Gene Therapy/European Society of Gene and Cell Therapy Public Engagement Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>01A8DBDB-47F0-4573-AAD2-7FFBFEDD5799</gtr:id><gtr:impact>Around 200 6th formers/lay public attended, stimulating many questions from the presenter

The radio presenter from Radio East Anglia expressed an interest in visiting our laboratory</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>5th Neuronopathic Gaucher Disease Family Conference, Reading Hilton, 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8DDD3F68-B62B-487C-A8A3-CBE176D3D637</gtr:id><gtr:impact>Patients, their families and other stakeholders attended this meeting hosted by the Gauchers Assocation Limited. The presentations stimulated many questions from the attendees afterwards

Nothing specific, to date</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have characterised inflammation occurring early in the knockout GBA mouse model</gtr:description><gtr:id>356AA6D0-74D0-4297-87BD-769925FEF289</gtr:id><gtr:impact>Too early as yet</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Pathology of GBA knockout mice</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2521ECF7-D5A0-41AC-8FDF-7413E60605A6"><gtr:id>2521ECF7-D5A0-41AC-8FDF-7413E60605A6</gtr:id><gtr:title>In vivo bioimaging with tissue-specific transcription factor activated luciferase reporters.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eb51617ff48dc2c2df156e38a48f7078"><gtr:id>eb51617ff48dc2c2df156e38a48f7078</gtr:id><gtr:otherNames>Buckley SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8AFD1530-9A5F-48A1-8596-835B47098F70"><gtr:id>8AFD1530-9A5F-48A1-8596-835B47098F70</gtr:id><gtr:title>Proof-of-concept: neonatal intravenous injection of adeno-associated virus vectors results in successful transduction of myenteric and submucosal neurons in the mouse small and large intestine.</gtr:title><gtr:parentPublicationTitle>Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b1c2a9ecdbc3572ce7ec4e387d0095b8"><gtr:id>b1c2a9ecdbc3572ce7ec4e387d0095b8</gtr:id><gtr:otherNames>Buckinx R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1350-1925</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0311616B-2B0A-4F05-AAF2-08D0872041B5"><gtr:id>0311616B-2B0A-4F05-AAF2-08D0872041B5</gtr:id><gtr:title>?-Glucosidase 2 (GBA2) activity and imino sugar pharmacology.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8ea2a151065bc1d4fa20f1bbd5904d7b"><gtr:id>8ea2a151065bc1d4fa20f1bbd5904d7b</gtr:id><gtr:otherNames>Ridley CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/01275E88-2ABD-4FA5-87ED-25276342BFAF"><gtr:id>01275E88-2ABD-4FA5-87ED-25276342BFAF</gtr:id><gtr:title>Increased glucocerebrosidase (GBA) 2 activity in GBA1 deficient mice brains and in Gaucher leucocytes.</gtr:title><gtr:parentPublicationTitle>Journal of inherited metabolic disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ed95dd2ffa3802e2b0b5dfab9f69a331"><gtr:id>ed95dd2ffa3802e2b0b5dfab9f69a331</gtr:id><gtr:otherNames>Burke DG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0141-8955</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DA424EE1-D5C6-42A6-8802-2B033BF13D60"><gtr:id>DA424EE1-D5C6-42A6-8802-2B033BF13D60</gtr:id><gtr:title>Evidence for contribution of CD4+ CD25+ regulatory T cells in maintaining immune tolerance to human factor IX following perinatal adenovirus vector delivery.</gtr:title><gtr:parentPublicationTitle>Journal of immunology research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/07f9bb2ec8c32f86e6418b6a0bdddd78"><gtr:id>07f9bb2ec8c32f86e6418b6a0bdddd78</gtr:id><gtr:otherNames>Nivsarkar MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2314-7156</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FC1EC948-5EAA-4C41-8C55-DC16D95CFB19"><gtr:id>FC1EC948-5EAA-4C41-8C55-DC16D95CFB19</gtr:id><gtr:title>Systemic gene delivery following intravenous administration of AAV9 to fetal and neonatal mice and late-gestation nonhuman primates.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9e4cb902cab54cae8b49c602593c22ca"><gtr:id>9e4cb902cab54cae8b49c602593c22ca</gtr:id><gtr:otherNames>Mattar CN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AD56CF77-EA34-42B6-9EBB-833FFB8206D8"><gtr:id>AD56CF77-EA34-42B6-9EBB-833FFB8206D8</gtr:id><gtr:title>Current therapies for the soluble lysosomal forms of neuronal ceroid lipofuscinosis.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/87e92fc148d83443cb059d032d3d9b99"><gtr:id>87e92fc148d83443cb059d032d3d9b99</gtr:id><gtr:otherNames>Wong AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/61FAD620-6217-4EB3-9337-409EB8EAD5EA"><gtr:id>61FAD620-6217-4EB3-9337-409EB8EAD5EA</gtr:id><gtr:title>In utero gene transfer to the mouse nervous system.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c8a1a8a31f9ba996499bf8bc3a890145"><gtr:id>c8a1a8a31f9ba996499bf8bc3a890145</gtr:id><gtr:otherNames>Rahim AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/53660FFB-E396-4642-90EB-DEF5F2A65D7C"><gtr:id>53660FFB-E396-4642-90EB-DEF5F2A65D7C</gtr:id><gtr:title>Perinatal systemic gene delivery using adeno-associated viral vectors.</gtr:title><gtr:parentPublicationTitle>Frontiers in molecular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e539d786838b9aaf0be5a6ec3a6cc586"><gtr:id>e539d786838b9aaf0be5a6ec3a6cc586</gtr:id><gtr:otherNames>Karda R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1662-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6327AD94-9348-4B8D-A2E4-28563EABC25A"><gtr:id>6327AD94-9348-4B8D-A2E4-28563EABC25A</gtr:id><gtr:title>Mitochondria and quality control defects in a mouse model of Gaucher disease--links to Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Cell metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/475d877ceec760cc4db02f32a29b38b3"><gtr:id>475d877ceec760cc4db02f32a29b38b3</gtr:id><gtr:otherNames>Osellame LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1550-4131</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/82DCDBE9-5BE4-4E2B-982A-9A48A6B8C2F5"><gtr:id>82DCDBE9-5BE4-4E2B-982A-9A48A6B8C2F5</gtr:id><gtr:title>Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c8a1a8a31f9ba996499bf8bc3a890145"><gtr:id>c8a1a8a31f9ba996499bf8bc3a890145</gtr:id><gtr:otherNames>Rahim AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000709</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>